Introduction
Sickle cell disease (SCD) is the most common inherited hemoglobin disorder. Particularly frequent in people of African descent, the disease is associated with numerous complications and early mortality. 1, 2 Major progress has been made in the management of SCD and this has improved patients' survival without curing the disease; 3 this includes implementation of antenatal counseling and neonatal screening programs, 3 screening and prevention of neurological complications, 4 prevention of pneumococcal infections, 5, 6 and the use of hydroxycarbamide 5, 7 and chronic transfusion therapy. 8 However, hematopoietic stem cell transplantation (HSCT) remains, to date, the only known curative therapy for SCD, [9] [10] [11] [12] offering a cure rate exceeding 90%. [9] [10] [11] [12] [13] [14] [15] [16] [17] Walters et al., in a recent review of HSCT in SCD children after HLA-identical sibling HSCT reported overall survival and event-free survival rates of 95% and 92%, respectively. 17 Similar results were reported in retrospective registrybased surveys from the Center for International Blood and Marrow Transplant Research 18 and the European Society for Blood and Marrow Transplantation 9,10,13 with overall survival rates of over 91%.
Despite a cure rate exceeding 90%, regardless of the stem cell source, HSCT is still under-used for patients with SCD. 9, 10 Limiting factors include the availability of suitable donors and, for the majority of patients for whom a matched sibling donor has been identified, the reluctance of families and physicians to consider transplantation because of possible transplant-related toxicity.
Umbilical cord blood transplantation (CBT) from a related family member has proved to be an effective alternative for patients with SCD, resulting in survival rates similar or superior to adult donor transplant 9, 10, 13, 19, 20 and lower probability of acute and chronic graft-versus-host diseases (GvHD). 9, 10 More recently, a promising, but still experimental, approach based on gene and cellular therapy methods has been proposed aiming to correct the sickle gene defect in the patient's own stem cells. 21, 22 With the emergence of the gene-therapy biotechnology to treat genetic disorders 22 and the improved outcomes of CBT, many directed public or private cord blood (CB) banking programs have been established for affected siblings who would benefit from a related HSCT. Consequently, cord blood banks (CBB) are now confronted with major challenges regarding storage and disposal of the units.
We report here our 20-year experience in two public family-directed cord blood banks for SCD.
Methods
Participants were pregnant women who had a child homozygous for SCD. Recruitment was carried out through referral addressed to the CBB by the clinician treating the affected child. All mothers, including those who refused prenatal diagnosis, were offered sibling CB banking. Participation was voluntary. Informed consent was obtained from the mother before delivery, in accordance with local ethical requirements. Collections were organized by two public banks, free of charge for the families. Both banks had a wide experience in unrelated CB banking and were affiliated to the French network of CBB accredited by the "Agence Nationale de Biomedecine".
The CBUs were reserved for family use and were shipped to the transplant center once the decision to proceed with transplantation was made. All mothers underwent a panel of mandatory serology testing prior to banking, which included hepatitis B and C viruses, HIV 1-2, HTLV I-II and syphilis.
The CBU were collected in the health care institution selected by the mother for child delivery. Twenty-seven institutions were involved and were contacted by the CBB. Informed consents were collected by midwives or designated medical personnel locally before delivery. Detailed instructions and training to local staff were provided by the CBB team. CBU collection kits, including a collection pack and materials necessary for harvesting, were sent to the contact team in the delivery hospital along with the standard regulatory forms. All CBUs were transported to the designated CBB to be processed within 24 hours of collection.
The CBBs policy was to process and store all the collected CBUs, independent of the unit volume, cell counts and HLA compatibility. Cell counts, cell viability, sterility tests, progenitor cell quantification and functional assays were performed for all CBUs. Due to related cost and absence of immediate patient indication for transplantation, histocompatibility testing was not conducted routinely, unless requested by the referring clinician. There was no volume reduction before cryopreservation. The CBUs were cryopreserved using a controlled-rate freezer, then transferred to the vapor phase of a liquid nitrogen storage tank and maintained at less than -150°C.
The CBUs and aliquots collected from mothers having positive infectious markers or awaiting results were stored in quarantine tanks. Abnormal results that could affect donor suitability were considered individually at the time a CBU was requested for transplantation.
Hemoglobin genotyping was not performed on CBU samples. Information about donor SCD status was available through the national neonatal screening database for genetic diseases. CBUs Once the decision to proceed with transplantation was made, confirmatory HLA typing was conducted. CBUs were thawed and shipped to the transplant unit for infusion. Total nucleated cells and CD34 + cell counts, viability and sterility tests were performed after thawing.
Data were collected from CBB databases, Eurocord registry and patient records. Neutrophil engraftment was defined as the first of three consecutive days with neutrophils 0.5x10 9 /L or more, and platelet engraftment as the first of three consecutive days with platelets 20x10 9 /L or more with no platelet transfusions for at least seven days before reconstitution.
Results
From 1995 to 2014, a total of 338 CBUs were collected with a sustained increase in the number of referrals for family CB banking for SCD over the years. These units were stored for 302 families, including 32 mothers recruited more than once. All collections were for an existing homozygous sibling. Fifteen families (5%) had more than one affected child. Figure 1 details the distribution of the CBUs collected in each CBB.
Characteristics of banked CBUs
Median values for specific quality parameters of the collected CBUs are shown in Table 1 . Sixty-one percent (n=207) of the collections exceeded 80 mL ( Figure 2 ) and 40% (n=135) exceeded 10.0x10 8 
total nucleated cell count (TNC).
Sixty-five percent (n=218) of the units had a minimal TNC of 5x10 8 (based on 20 kg recipient, a target dose of ≥2.5x10
7 nucleated cells/kg), considered suitable for pediatric transplantation according to the US FDA 23 criteria for banking CBUs and 44% of the units (n=148) exceeded the minimal pre-freezing thresholds for cell counts and volume adopted by many unrelated CBBs [24] [25] [26] [27] (i.e. volume >40 mL and TNC >9x10 8 ).
A microbial contamination rate of 3.5% was observed in our cohort as 12 CBUs failed sterility testing; these units were stored because antimicrobial sensitivity results did not preclude their use for transplantation with the provision of appropriate antibiotics. Eighty-four CBUs (25%) had positive hepatitis B serological markers: 76% (n=64) of these were due to positive anti-HBs and/or anti-HBc antibodies with negative HBs antigen. Two units tested positive for hepatitis C (HCV) antibody, but HCV RNA was not detected by PCR, despite maternal active HCV infection. All CBUs were negative for HIV.
HLA-typing was carried out for 145 donor-recipient pairs (43% of the collected CBU) upon request of the referring physicians (Table 2) . Forty-four units had a full HLA antigen match with the intended recipient: these represented 30% of the typed units and 13% of all collected units.
Eleven percent (n=37) of the collections had homozygous SCD and 45% (n=152) a carrier disease status ( Figure  3 ). Of the 145 HLA typed CBU, 8% (n=11) were homozygous for SCD, and 26% (n=38) were both HLA identical to the recipient and had normal hemoglobin or sickle cell carrier status, thus considered as "potential graft source" for the intended sibling.
To date, 28 units were released for transplantation either alone (CBT, n=23) or in combination with a bone marrow (BM) graft from the same donor (CBT+BMT, n=5), reflecting a utilization rate of 8% for the whole cohort over 20 years, and 19% transplant rate for the typed units. Another 13 HLA-identical CBUs with adequate cell dose to perform transplantation remained in storage for future use, as their intended recipient was not an immediate indication for transplantation (n=9) or decided not to undergo the procedure (n=4) because of transplant-related risks. Three HLA identical CBUs were deemed unsuitable for transplantation due to their biological features: 2 units were homozygous for HbS and one unit had low cell counts (2.7 x10 7 TNC/kg and 0.2 x10 6 CD34 + cell/kg) ( Table 2) .
Of further interest, 41% (n=137) of the collected CBUs were referred from a single hematologic center. 9, 11 Histocompatibility testing was requested and performed for 87% (n=119) of these CBUs and 30% (n=35) were HLA identical to the affected sibling. To date, 25 of these collections were used for CBT. This represents an 18% (25 of 137) utilization rate for collections referred from this center, 21% (25 of 119) transplant rate for typed units, and a 71% (25 of 35) transplant rate when a matched sibling is available. These are noteworthy rates and reflect a 2.3-fold increase in the utilization rate when the collections are requested by clinicians willing to use CBUs to transplant the affected child once transplantation is indicated. When compared to other referrals that were not affiliated to a transplant center (n=201), only 29 CBUs (14%) were typed for HLA, of which 3 units were used for transplantation; this reflects a 1.5% (3 of 201) utilization rate for the units referred from these centers, 10% (3 of 29) of the typed units, and 33% (3 of 9) of the HLA-identical units.
Transplant characteristics
Over a period of 20 years, 28 units were released for transplantation to 28 patients. Characteristics of transplanted patients are shown in Table 3 . The median age of recipients at transplantation was 6.8 (3.2-13.6) years. All patients for whom data were available (n=25) received a conditioning regimen including busulfan, cyclophosphamide and anti-thymocyte globulin (ATG). All CBUs were HLA identical to the intended recipient, and 54% of the donors were sickle cell carriers. The CBUs were transplanted after a median storage time of 2.2 years (range 0.4-8.1) ( ) were provided by the CBUs. The median time to engraftment was 28 days (range 17-60) for neutrophils, and 54 days (range 12-91) for platelets (n=18). All but one patient engrafted for neutrophils before day 60, with a median time of 33 days after single CBT and 26 days after BMT+CBT. Chimerism at day 100 for those patients with available data (n=22) was 100% donor for 9 patients (41%) and 60-80% donor for 12 patients (55%). At last follow up, donor chimerism exceeded 80% for all patients with available data.
Notably, one patient transplanted in 1996 with an adequate cell dose (4x10 7 TNC/kg) had primary graft failure; this patient also failed to engraft after a second transplant using the BM collected from the same sibling donor. At last follow up, the patient was alive with autologous reconstitution and remained anemic but free of vasoocclusive events. This is due to sustained increase in fetal hemoglobin production, as previously reported after autologous reconstitution in patients affected by SCD 11, 28 and β-hemoglobin disorders. 29 Five patients who received single CBT experienced grade I-II acute GvHD that required steroids in 4 cases. One recipient of combined CB+BM transplant developed limited liver chronic GvHD, which was the only chronic GvHD event reported for the entire cohort.
All 28 patients are alive and free of SCD symptoms to date (except the sole case of persistent anemia after primary graft failure), with a median follow up of 4.3 years (4 months-14 years).
Discussion
The aim of this study was to investigate whether sibling CBU collections had sufficient cellular quantity and quality to support allogeneic CBT of the intended recipient and to assess the utilization pattern of these collections.
Family CB banking differs in many important aspects from public CBU donations. Besides the cost related to this stem cell source, when less expensive alternatives using the sibling BM are possible, there are major challenges related to cellular characteristics of the collections, such as the long-term storage and low utilization rate noted by many teams 13, [30] [31] [32] and confirmed in our cohort. The cellular and biological characteristics of our banked units were comparable to those reported by other directed CBB programs 13, 26, 33 with a utilization rate reaching 8% of the 338 CBUs collected over 20 years, and 19% of the typed units. Similar low utilization rates of banked sibling CBUs for hematologic disorders have been reported by many authors. [30] [31] [32] [33] Both of our CBBs had previously published their experience 13 in banking sibling CBUs for malignant and nonmalignant disorders, with more than 400 directed CBUs collected in one bank and 111 units (80% for SCD affected siblings) in the second, a utilization rate for HLA identical sibling transplants of 3% and 9%, respectively, and 5-year overall survival of 83% and 100%, respectively, in the subgroup of patients with hemoglobin disorders. 11, 13 Most of the patients in our cohort were included in these studies. Adequate volume and TNC dose are critical factors in achieving a successful CB transplantation; therefore, the use of procedures that might increase collection volume or decrease cell loss during processing is especially important in family CB banking. While 65% of our CBUs had cellular characteristics (minimal collected TNC count of 5x10 8 ) adequate to support allogeneic CBT in the pediatric setting, 26, 34 only 13% (n=45) of our collections provided the TNC dose and volume recommended for unrelated CBU banking (initial volume >80 mL and TNC >18x10 8 ). However, the low cellular content should not be a limitation for the use of these CBU, 31, 33 particularly when there is an opportunity to increase the cell dose by combining CB with BM collected from the same sibling donor, an approach that proved to be effective with excellent overall survival and low incidence of GvHD, as noted by many authors. 13, 30, 31, 35 Indeed, all but one of the patients transplanted in our H. Rafii et al. 980 haematologica | 2017; 102(6) cohort engrafted within less than 60 days. Adding the same donor's BM to the CBUs with low cell counts probably improved the engraftment rate of our patients. The 3.5% bacterial contamination rate observed in our cohort was comparable to those reported in other studies; 33, 34 bacterial contaminations could be addressed at the time of transplantation with prophylactic antibiotics if necessary.
Homozygous SCD was detected in 11% of the collections, a lower rate than might be expected in autosomal recessive genetic disorders. This might be explained by the quite frequent antenatal diagnosis testing performed in this high-risk population.
Many important questions require further investigation, including the cost related to long-term storage of this graft source and its low utilization rate.
Ideally, the CBUs reported in our cohort should have been collected from families at risk of transmitting homozygous SCD, rather than those with an affected child. Storage-related cost remains a major limitation to such an ambitious program, when faced with the low utilization rate of these units.
In our cohort, 43% of the units were typed for HLA upon the request of the referring physicians, and 30% of the typed units were HLA-identical to the intended recipient; an expected proportion that reflects the 25% probability of finding a matched sibling donor. To limit the unnecessary long-term storage and its associated costs, HLA testing and identification of SCD status for all collections could be implemented, so a better-informed decision could be made about keeping or disposing of those units with a low usage rate, such as non-HLA-identical units or those with HbS homozygous status. However, the deciSibling cord blood banking for sickle cell disease haematologica | 2017; 102 (6) 981 Table 5 . Characteristics of the combined cord blood + bone marrow grafts. sion-making process must be managed with caution; non-HLA-identical CBUs could be kept to transplant homozygous identical siblings resulting from future pregnancies. Moreover, alternative experimental treatments might emerge in the future to support haploidentical-related allogeneic CBT 36 or autologous CBT in the setting of gene therapy. [37] [38] [39] [40] [41] [42] Finally, enhancing the utilization rate of the banked unit will also achieve a significant reduction in storage needs and related costs. The transplantation experience reported here with a single center being involved in most of the transplants, strongly suggests that close collaboration with clinical and transplant teams willing to support CBT of the affected sibling is likely to increase the proportion of transplants using directed CBUs. An increase in the awareness of the excellent outcomes of CBT in this setting is also crucial to overcome the reluctance of physicians and families to consider transplant.
However, despite the increase in number of homozygous cases of SCD in the developed countries and the excellent transplant outcomes, referrals for transplantation remain limited, as reported by our group in a recent review of sibling transplants. 10 The current study demonstrates that, despite the challenges associated with public directed CBB programs, sibling CBU represents a useful stem cell resource for families with specific medical indications, such as a child with sickle cell anemia or other genetic conditions that could benefit from a related transplant. These families should be encouraged to bank the CBUs from siblings. Family banking may yield good quality HLA-identical CBUs, with post-transplant outcomes and survival similar or superior to other stem cell sources.
The potential scope of medically indicated sibling cord blood banking is considerable, including hemoglobin disorders, as well as genetic and metabolic diseases. For this reason, banks should adopt a more comprehensive approach for the identification and collection of CBUs for family-directed uses, and work closely with the clinical and transplant teams to optimize the use of these units.
